WallStreetZenWallStreetZen

NASDAQ: ALXO
Alx Oncology Holdings Inc Stock

$1.72-0.11 (-6.01%)
Updated Oct 3, 2024
ALXO Price
$1.72
Fair Value Price
$0.12
Market Cap
$90.60M
52 Week Low
$1.68
52 Week High
$17.83
P/E
-0.47x
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$171.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$135M
Beta
1.39
Next Earnings
Nov 11, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALXO Overview

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALXO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALXO ($1.72) is overvalued by 1,319.45% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALXO ($1.72) is not significantly undervalued (1,319.45%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALXO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALXO due diligence checks available for Premium users.

Be the first to know about important ALXO news, forecast changes, insider trades & much more!

ALXO News

Valuation

ALXO fair value

Fair Value of ALXO stock based on Discounted Cash Flow (DCF)
Price
$1.72
Fair Value
$0.12
Overvalued by
1,319.45%
ALXO ($1.72) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALXO ($1.72) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALXO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALXO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.47x
Industry
-109.51x
Market
26.22x

ALXO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
5.92x
ALXO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALXO's financial health

Profit margin

Revenue
$0.0
Net Income
-$39.4M
Profit Margin
0%
ALXO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$214.6M
Liabilities
$55.3M
Debt to equity
0.35
ALXO's short-term assets ($168.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALXO's short-term assets ($168.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALXO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.6M
Investing
$907.0k
Financing
$27.2M
ALXO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALXO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALXO$90.60M-6.01%-0.47x0.57x
IFRX$91.86M+1.96%-1.75x1.03x
EPRX$92.26M-1.89%-3.41x6.22x
CTMX$88.27M-1.74%8.07x-2.83x
FBLG$93.17M-1.12%-3.96x-39.03x

Alx Oncology Holdings Stock FAQ

What is Alx Oncology Holdings's quote symbol?

(NASDAQ: ALXO) Alx Oncology Holdings trades on the NASDAQ under the ticker symbol ALXO. Alx Oncology Holdings stock quotes can also be displayed as NASDAQ: ALXO.

If you're new to stock investing, here's how to buy Alx Oncology Holdings stock.

What is the 52 week high and low for Alx Oncology Holdings (NASDAQ: ALXO)?

(NASDAQ: ALXO) Alx Oncology Holdings's 52-week high was $17.83, and its 52-week low was $1.68. It is currently -90.35% from its 52-week high and 2.38% from its 52-week low.

How much is Alx Oncology Holdings stock worth today?

(NASDAQ: ALXO) Alx Oncology Holdings currently has 52,671,790 outstanding shares. With Alx Oncology Holdings stock trading at $1.72 per share, the total value of Alx Oncology Holdings stock (market capitalization) is $90.60M.

Alx Oncology Holdings stock was originally listed at a price of $30.00 in Jul 17, 2020. If you had invested in Alx Oncology Holdings stock at $30.00, your return over the last 4 years would have been -94.27%, for an annualized return of -51.07% (not including any dividends or dividend reinvestments).

How much is Alx Oncology Holdings's stock price per share?

(NASDAQ: ALXO) Alx Oncology Holdings stock price per share is $1.72 today (as of Oct 3, 2024).

What is Alx Oncology Holdings's Market Cap?

(NASDAQ: ALXO) Alx Oncology Holdings's market cap is $90.60M, as of Oct 4, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alx Oncology Holdings's market cap is calculated by multiplying ALXO's current stock price of $1.72 by ALXO's total outstanding shares of 52,671,790.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.